Brave Asset Management’s Oncolytics Biotech ONCY Stock Holding History

Brave Asset Management’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,000	Closed	-$21.9K	–	172
2025 Q4	$21.9K	Hold	25,000	–	–	0.01%	164
2025 Q3	$35K	Hold	25,000	–	–	0.01%	165
2025 Q2	$19.1K	Hold	25,000	–	–	0.01%	162
2025 Q1	$13.7K	Hold	25,000	–	–	﹤0.01%	161
2024 Q4	$23.1K	Hold	25,000	–	–	0.01%	157
2024 Q3	$22K	Hold	25,000	–	–	0.01%	162
2024 Q2	$24.7K	Hold	25,000	–	–	0.01%	151
2024 Q1	$26.8K	Hold	25,000	–	–	0.01%	158
2023 Q4	$33.9K	Hold	25,000	–	–	0.01%	151
2023 Q3	$54.9K	Buy	25,000 +15,000	+150%	+$36.6K	0.02%	137
2023 Q2	$26.4K	Buy	+10,000	New	+$16.6K	0.01%	150
2023 Q1	–	Sell	-20,000	Closed	-$32.8K	–	158
2022 Q4	$32.8K	Hold	20,000	–	–	0.01%	145
2022 Q3	$25K	Hold	20,000	–	–	0.01%	140
2022 Q2	$20K	Hold	20,000	–	–	0.01%	141
2022 Q1	$32K	Hold	20,000	–	–	0.01%	153
2021 Q4	$28K	Hold	20,000	–	–	0.01%	151
2021 Q3	$42K	Hold	20,000	–	–	0.01%	146
2021 Q2	$55K	Buy	20,000 +10,000	+100%	+$30.6K	0.02%	149
2021 Q1	$38K	Buy	+10,000	New	+$29.8K	0.01%	144

Other funds holding ONCY

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SFP

Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return

Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Brave Asset Management's ONCY Position: Q1 2026 in Review

Brave Asset Management sold out of Oncolytics Biotech (ONCY) in Q1 2026, closing a stake of 25,000 shares — an estimated $21.9K sold.

Brave Asset Management first reported a position in ONCY in Q1 2021 and held it in 19 quarters. The position peaked at $55K in Q2 2021. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

Brave Asset Management reported no remaining Oncolytics Biotech position as of Q1 2026 after selling out during the quarter.
Brave Asset Management sold 25,000 Oncolytics Biotech shares in Q1 2026, an estimated $21.9K.
Brave Asset Management first reported a position in Oncolytics Biotech in Q1 2021 and held it in 19 quarters.
Brave Asset Management's Oncolytics Biotech position peaked at $55K in Q2 2021.
59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Brave Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.